UK-basedcontract research organization (CRO) Chiltern has announced its expansion plans in Asia-Pacific.
Chiltern has established two new offices and launched operations in Australia and Singapore–with Singapore acting as the hub for its operations in Southeast Asia. This builds further upon Chiltern’s well established operation in India. Chiltern is also establishing operations in China.
Chiltern’s Asia-Pacific operations will be led by Umakanta Sahoo,Executive Director, Asia-Pacific. “Chiltern’s expansion will provide a broad platform from which global pharmaceutical and biotech Sponsors can expand their geographic reach with confidence and enhance patient recruitment in the Asia-Pacific region,” stated Sahoo.
Glenn Kerkhof, Chiltern’s CEO, stated, “Asia-Pacific is one of the foremost emerging markets in our industry. With the current expansion of pharmaceutical R & D needs into the Asia-Pacific region, Chiltern is well positioned to meet the needs this growth entails. We are very pleased to provide our clients with access to this market while extending our focus on the delivery of high quality, responsive and better value services to our customers.”